SCHEMBL395675

SCHEMBL395675

CCN(CC)C(C(N)=O)n1c(C)c(C(=O)O)c(C)c1C=C1C(=O)Nc2cc(NC(=O)Nc3cccc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)c3)ccc21

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 9/20 0.61
▸ NTRK2 Q16620 8/20 0.61
▸ RAF1 P04049 4/20 0.61
▸ AURKA O14965 1/20 0.61
▸ SRC P12931 1/20 0.61
▸ BRAF P15056 3/20 0.45
▸ NTRK3 Q16288 2/20 0.42
▸ NR2E1 Q9Y466 1/20 0.42
▸ EPHB4 P54760 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ BCR P11274 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396895 0.97 NTRK1 (0.66) NTRK1NTRK2RAF1AURKASRC
SCHEMBL394406 0.97 NTRK2 (0.59) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396341 0.95 NTRK1 (0.63) NTRK1NTRK2RAF1AURKASRC
SCHEMBL398007 0.91 NTRK1 (0.60) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396192 0.88 NTRK1 (0.61) NTRK1NTRK2RAF1AURKASRC
SCHEMBL395945 0.86 NTRK1 (0.51) NTRK1NTRK2RAF1AURKASRC
SCHEMBL396230 0.86 NTRK1 (0.56) NTRK1NTRK2RAF1AURKASRC
SCHEMBL394525 0.85 FLT3 (0.51) NTRK1AURKANTRK3CSF1R
SCHEMBL397637 0.85 NTRK2 (0.58) NTRK1NTRK2RAF1AURKASRC
SCHEMBL4124627 0.83 NTRK1 (0.71) NTRK1NTRK2RAF1AURKASRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback